AVT32-DRL_PB + Keytruda

Phase 1Recruiting

0 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Melanoma

Conditions

Melanoma

Trial Timeline

Jun 19, 2026 → Apr 14, 2028

NCT ID

NCT07475572

About AVT32-DRL_PB + Keytruda

AVT32-DRL_PB + Keytruda is a phase 1 stage product being developed by Dr. Reddy's Laboratories for Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07475572. Target conditions include Melanoma.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma were approved

Approved (4) Terminated (2) Active (14)

✅dabrafenib + trametinibNovartisApproved

✅ZelborafRocheApproved

✅Nivolumab + RelatlimabBristol Myers SquibbApproved

✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved

❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3

🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07475572	Phase 1	Recruiting	Jun 19, 2026	Apr 14, 2028	Melanoma

Competing Products

20 competing products in Melanoma

See all competitors

Product	Company	Stage	Hype Score
mRNA-4157 + Pembrolizumab	Merck	Phase 2	39
Binimetinib Oral Tablet	Biotrial	Phase 1	15
Tasisulam-sodium + Paclitaxel	Eli Lilly	Phase 3	32
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT01 + [68Ga]VMT02	Perspective Therapeutics	Phase 1	23
FYB206 + Keytruda	Formycon AG	Phase 1	23
PLX3397	Daiichi Sankyo	Pre-clinical	26
PLX3397 + Pembrolizumab	Daiichi Sankyo	Phase 1/2	24
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
DS-8273a + Nivolumab	Daiichi Sankyo	Phase 1	29
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	21
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	42
CP-461	Astellas Pharma	Phase 2	27
YM155	Astellas Pharma	Phase 2	35
YM155 + Docetaxel	Astellas Pharma	Phase 2	35
Denileukin diftitox	Eisai	Phase 2	35
E7080	Eisai	Phase 1	29
lenvatinib + pembrolizumab	Eisai	Phase 2	35
MORAb-004 (monoclonal antibody)	Eisai	Phase 2	35
Pembrolizumab + Lenvatinib	Eisai	Phase 2	39